Welcome to our dedicated page for AlphaTON Capital news (Ticker: ATON), a resource for investors and traders seeking the latest updates and insights on AlphaTON Capital stock.
AlphaTON Capital Corp (NASDAQ: ATON) generates news at the intersection of technology, digital assets, decentralized AI infrastructure, and advanced healthcare. The company describes itself as a public technology company scaling the Telegram super app while managing a strategic reserve of digital assets and building exposure to The Open Network (TON) ecosystem. Its announcements often combine capital markets activity with updates on AI compute deployments, Telegram-based applications, and tokenization initiatives.
Readers following ATON news can expect frequent coverage of financing transactions such as private placements, at-the-market offerings, and registered direct offerings supported by shelf registration statements. These items detail how AlphaTON raises capital to fund GPU deployments for Cocoon AI, expand data center capacity, and support working capital and general corporate purposes.
Another major category of AlphaTON news involves decentralized AI infrastructure. The company has issued multiple releases about securing and deploying NVIDIA H200, B200 and B300 GPUs, entering into a multi-year colocation agreement with atNorth in Sweden, and contributing confidential compute power to Telegram’s Cocoon AI network. These updates describe how AlphaTON is building privacy-preserving, decentralized AI infrastructure integrated with Telegram’s ecosystem.
News items also cover strategic investments and ecosystem partnerships, including investment in Alpha Liquid Terminal, plans for tokenized financial products, and initiatives like the #OwnYourNode program that aim to democratize GPU ownership. In addition, AlphaTON reports on its legacy biotech activities and its intention to launch a decentralized, AI-native biotech platform for rare cancers, starting with mesothelioma.
For investors and observers, the ATON news feed offers a way to track how the company combines digital asset treasury management, AI infrastructure build-out, Telegram-based financial applications, and biotech-related initiatives under a single Nasdaq-listed entity.
AlphaTON Capital (Nasdaq: ATON) announced a strategic partnership with Morpheus AI on October 13, 2025 to make Morpheus the preferred AI infrastructure provider for AlphaTON portfolio companies building on TON and Telegram.
The MOU covers decentralized inference, a tools marketplace, and decentralized storage to accelerate agentic AI development and reduce integration time for AI agents. The deal highlights use of $MOR tokens within the ecosystem and a knowledge-sharing collaboration between the two firms.
AlphaTON Capital (NASDAQ: ATON) announced Nasdaq publicly congratulated the company for pioneering a blockchain-based cancer research tokenization initiative; the recognition was displayed on the Nasdaq Tower in Times Square on October 10, 2025. AlphaTON is partnering with Cyncado Therapeutics to fund oncology programs via tokenized assets, aiming to increase liquidity, improve transparency of fund allocation, lower investor minimums, and accelerate R&D timelines. The company said the model helped advance multiple research programs and that it plans to expand tokenization to more therapeutic areas and institutional partners.
AlphaTON Capital (NASDAQ: ATON) announced that CIO and Executive Chairman Enzo Villani was interviewed live at Nasdaq MarketSite with IPO Edge on October 2, 2025. The fireside chat covered the TON blockchain, Telegram ecosystem growth, platform security, communication privacy, and AlphaTON's institutional treasury strategy.
AlphaTON described a three-pillar approach: direct TON acquisition and yield activities, validator and staking operations, and incubating Telegram mini apps. The company highlighted connections to industry partners and noted Telegram's reach of over one billion monthly active users.
AlphaTON Capital (NASDAQ: ATON) and its oncology subsidiary Cyncado Therapeutics announced a non-binding LOI to evaluate tokenization of the economic rights for TT-4, an oral A2B receptor antagonist targeting mesothelioma. Cyncado is in final start-up preparations for TT-4 with first-patient dosing targeted for Q1 2026 under its existing FDA-cleared TT-10-101 protocol, followed by a mesothelioma-focused study at major U.S. cancer centers. Preclinical results cited include >90% tumor growth inhibition, 60% complete responses with anti-PD-1 combination, and >90-day survival in combination groups. The LOI is exploratory and non-binding; any tokenization would preserve traditional licensing and financing pathways and require board approval and regulatory clearance.
Health In Tech (NASDAQ: HIT) has signed a strategic Letter of Intent (LOI) with AlphaTON Capital (NASDAQ: ATON) to develop HITChain, a blockchain-powered healthcare insurance claims processing platform built on The Open Network (TON). The platform aims to address inefficiencies in the $4.5 trillion U.S. healthcare market, where claims administration currently costs over $300 billion annually.
The collaboration combines Health In Tech's insurance expertise with AlphaTON's blockchain infrastructure to create an immutable, transparent claims ecosystem. Health In Tech will provide insurance domain expertise and established industry relationships, while AlphaTON will contribute blockchain development expertise, smart contract architecture, and security protocols.
The platform seeks to reduce administrative costs, improve stakeholder trust, and streamline claims processing for employers, providers, brokers, and insurers.AlphaTON Capital (Nasdaq: ATON) has successfully completed major financing transactions totaling $71 million, including a $36.2 million private placement and a $35 million loan facility from BitGo Prime. The company immediately deployed $30 million to acquire TON tokens, establishing itself as one of the largest global TON holders.
Led by CEO Brittany Kaiser and Executive Chairman Enzo Villani, AlphaTON Capital aims to expand its TON treasury to $100 million in Q4 2025. The company's strategy focuses on network validation, staking operations, and ecosystem development within Telegram's platform, which serves over one billion monthly active users.
AlphaTON Capital Corp (formerly Portage Biotech) announced a strategic transformation to become a specialized digital asset treasury company focused on the TON blockchain and Telegram ecosystem. The company appointed Brittany Kaiser as CEO and will trade under the new ticker "ATON" starting September 4, 2025.
The company secured $38.2 million through private placement and a $35 million loan facility from BitGo Prime to acquire approximately $100 million worth of TON tokens. The strategy includes building a TON treasury, implementing yield generation through validation and staking, and developing ecosystem projects within Telegram's billion-user platform.
Strategic partnerships include notable firms like BitGo, Animoca Brands, and SkyBridge, with advisors including Anthony Scaramucci and Michael Terpin.